What’s on Teva’s mind?

Published: 2012-11-07 06:59:00

Updated: 2012-11-07 06:59:00

Shares of the mid-tier pharmaceutical firms has been in steep rally, since a health ministry official said that generic drug giant Teva enters into an agreement with a Korean firm over possible merger.

So far, several Korean firms, such as Myungmoon Pharm, Yuyu Pharm, Kukje Pharm and Korea Uni...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK